Appeals Court Says Prometheus Meets Machine/Transformation Test; Impact on Gene Patents Uncertain
December 22, 2010
Appeals Court Says Prometheus Meets Machine/Transformation Test; Impact on Gene Patents Uncertain
Diagnostic developers and legal experts have been keeping a close watch on Prometheus since the Federal Circuit Court of Appeals' handling of diagnostic method patents in that case may impact the AMP v. USPTO gene-patenting lawsuit that is pending review by the same court.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- ACLU, PUBPAT Seek to Challenge Patentability of Isolated Genes Before Supreme Court
October 12, 2011 / Pharmacogenomics Reporter - UPDATE: Appeals Court Decides Isolated DNA Patentable, Myriad's Analytical Method Claims Not
August 3, 2011 / Pharmacogenomics Reporter - Game On: Court Ruling on Myriad Patents to Kick off Protracted Legal Battle Over DNA Patentability
March 31, 2010 / Pharmacogenomics Reporter - Federal Circuit Judges Considered USPTO Policy, Industry Impact in Ruling on Myriad's Gene Patents
August 22, 2012 / Pharmacogenomics Reporter - USPTO Hearing on Confirmatory Gene Testing Raises Calls for Reform Outside Patent System
February 22, 2012 / Pharmacogenomics Reporter